Skip to main content
. 2017 Jan 31;8(9):15621–15631. doi: 10.18632/oncotarget.14919

Figure 5. Meta-analysis of the HR for OS/DSS for ovarian cancer patients depending on CD103+ TILs status, random effects model.

Figure 5